Supernus, Inc. (SUPN)
| Market Cap | 6.06B +59.2% |
| Revenue (ttm) | 1.37B +16.4% |
| Net Income | 450.00M +248.8% |
| EPS | 3.55 +250.9% |
| Shares Out | 207.72M |
| PE Ratio | 8.21 |
| Forward PE | 7.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,079,297 |
| Open | 29.21 |
| Previous Close | 29.04 |
| Day's Range | 28.69 - 29.75 |
| 52-Week Range | 25.92 - 42.81 |
| Beta | 1.13 |
| Analysts | Strong Buy |
| Price Target | 54.14 (+85.6%) |
| Earnings Date | Oct 29, 2026 |
About SUPN
Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The companyās core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphin... [Read more]
Financial Performance
In 2025, Supernus's revenue was $1.24 billion, an increase of 4.29% compared to the previous year's $1.19 billion. Earnings were $210.00 million, an increase of 2900.00%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for SUPN stock is "Strong Buy." The 12-month stock price target is $54.14, which is an increase of 85.60% from the latest price.
News
Supernus Transcript: Jefferies Global Healthcare Conference
The completed Indivior merger creates a ~$2.2B-revenue business with leverage below 1x and a focus on growing key CNS products, advancing pipeline assets and pursuing deals. SUBLOCADE, ONAPGO and Qelbree updates outlined growth drivers and 2027 considerations.
Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous sys...
Supernus initiated with a Buy at BofA
As previously reported, BofA analyst Chi Fong initiated coverage of Supernus (SUPN) with a Buy rating and $47 price target The new Supernus, formed through the merger of Indivior andā¦
Supernus initiated with a Buy at BofA
BofA initiated coverage of Supernus (SUPN) with a Buy rating and $47 price target
Supernus price target raised to $87 from $67 at Cantor Fitzgerald
Cantor Fitzgerald analyst Kristen Kluska raised the firmās price target on Supernus (SUPN) to $87 from $67 and keeps an Overweight rating on the shares.
Supernus resumed with an Overweight at Piper Sandler
Piper Sandler analyst David Amsellem resumed coverage of Supernus (SUPN) with an Overweight rating and $47 price target following the closing of its merger with Indivior. The firm believes theā¦
Supernus price target lowered to $37 from $55 at Stifel
Stifel lowered the firmās price target on Supernus (SUPN) to $37 from $55 and keeps a Hold rating on the shares.
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN)1 today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuti...
Supernus reports Q3 adjusted operating earnings $55.2M vs. $41.9M last year
Reports Q3 revenue $226.8M, consensus $217.56M. The company said, āOur strong operating execution year-to-date delivered total revenue growth of 29%, which shows the continued momentum across our comm...
Supernus sees 2026 revenue $875M-$900M vs. prior $860M-$890M
Consensus $873.98M. Sees 2026 adjusted operating earnings $160M-$180M vs. $150M-$180M prior.
Supernus Earnings Call Transcript: Q3 2026
Q3 revenue hit a record $226.8M, with strong growth across key products and raised standalone FY 2026 guidance. The Indivior merger was approved by shareholders and expected to close Nov. 2.
Supernus Earnings release: Q3 2026
Supernus released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Supernus Quarterly report: Q3 2026
Supernus has published its Q3 2026 quarterly earnings report on October 29, 2026.
Supernus Announces Third Quarter 2026 Financial Results
ROCKVILLE, Md., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Huron to replace Supernus in S&P 600 at open on November 3
Huron Consulting Group (HURN) will replace Supernus Pharmaceuticals (SUPN) in the S&P SmallCap 600 before the opening of trading on Tuesday, November 3, instead of Monday, November 2. S&P SmallCapā¦
Supernus announces orphan drug exclusivity for ONAPGO
The company states: āSupernus (SUPN) announced that the FDA has recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in adults ...
Supernus Announces Orphan Drug Exclusivity for ONAPGO⢠(apomorphine HCl)
Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-ye...
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
ROCKVILLE, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus price target lowered to $55 from $60 at BofA
BofA lowered the firmās price target on Supernus (SUPN) to $55 from $60 and keeps a Buy rating on the shares. Ahead of Q3 earnings, the firm is lowering Onapgoā¦
Supernus Proxy statement: Proxy filing
Supernus filed a proxy statement on October 6, 2026, providing details for shareholder voting and corporate governance matters.
Supernus Proxy statement: Proxy filing
Supernus filed a proxy statement on September 11, 2026, providing details for shareholder voting and corporate governance matters.
Supernus Transcript: Wells Fargo 21st Annual Healthcare Conference
The company is leveraging R&D and M&A to drive growth, maintaining strong revenue despite LOEs. Qelbree leads the ADHD franchise with rapid growth and significant market potential, while ONAPGO and ZURZUVAE expand the portfolio in movement disorders and women's health. Pipeline innovation focuses on novel CNS therapies.
Supernus Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The conference highlighted strong growth in CNS therapeutics, with Qelbree and ONAPGO outperforming expectations and Zurzuvae gaining momentum in postpartum depression. The pending Indivior merger is set to accelerate diversification and R&D, while the pipeline advances novel treatments for depression and epilepsy.
Supernus Pharmaceuticals to Participate in September Investor Conferences
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...
Chloe Kim Teams Up with QelbreeĀ®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
ROCKVILLE, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Professional snowboarder, Chloe Kim, is partnering with Supernus Pharmaceuticals as a compensated ambassador to discuss her journey with attention-def...